Merrimack Pharmaceuticals
MACK
#8831
Rank
NZ$0.39 B
Marketcap
NZ$26.98
Share price
0.00%
Change (1 day)
3.38%
Change (1 year)

Earnings for Merrimack Pharmaceuticals (MACK)

Earnings in 2024 (TTM): -NZ$3.71 Million

According to Merrimack Pharmaceuticals's latest financial reports the company's current earnings are N/A. In 2023 the company made an earning of -NZ$3.89 Million a decrease over its 2022 earnings that were of -NZ$3.88 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Merrimack Pharmaceuticals from 2010 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -NZ$3.71 Million-4.51%
2023 -NZ$3.89 Million0.09%
2022 -NZ$3.88 Million-16.9%
2021 -NZ$4.67 Million-49.89%
2020 -NZ$9.31 Million-75.39%
2019 -NZ$37.83 Million-68.58%
2018 -NZ$0.13 Billion-19.4%
2017 -NZ$0.15 Billion-36.46%
2016 -NZ$0.24 Billion2.54%
2015 -NZ$0.23 Billion96.78%
2014 -NZ$0.12 Billion-45.44%
2013 -NZ$0.22 Billion
2010 -NZ$82.81 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
NZ$13.88 B-344,855.64%๐Ÿ‡ซ๐Ÿ‡ท France
Geron
GERN
-NZ$33.96 Million 742.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Clovis Oncology
CLVS
-NZ$0.39 Billion 9,523.90%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-NZ$51.79 Million 1,185.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Eterna Therapeutics
ERNA
-NZ$29.47 Million 631.30%๐Ÿ‡บ๐Ÿ‡ธ USA